Skip to main content

Advertisement

Figure 2 | SpringerPlus

Figure 2

From: Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy

Figure 2

Progression-free survival (PFS) and overall survival (OS) according to relapse-free survival (RFS) in the platinum combination therapy group. (A) PFS: RFS <6 months, median PFS = 3.6 months; RFS ≥6 months, median PFS = 5.6 months. (B) OS: RFS <6 months, median OS = 16.5 months; RFS ≥6 months, median OS = 25.3 months.

Back to article page